期刊文献+

研究MRI分子影像学发展的必备条件 被引量:2

Key Points of Study for MR Molecular Image
下载PDF
导出
摘要 研究MR分子影像学必须从二方面进行,一是开发高灵敏度、高分辨率的MR设备,二是建立特异性MRI分子探针。MRI活体、无辐射、无损伤的优势必将成为未来分子影像学和最具发展前景的设备。MRI分子探针必须具备生物学兼容性,能够在人体内参与正常生理代谢过程,不影响生理功能,对人体没有任何伤害,包括本身和遗传、致畸;必须能够克服体内生理屏障,如血脑屏障、血管壁、细胞膜等。靶分子结合必须具有高度的灵敏度、特异性,容易解离,方法简单,容易成像,便于观察和监测。 Two aspects must be considered when studying MR molecular imaging: One is to develop supper sensitivity and high resolution MR equipment. The other is to develop the specific MRI molecular target probe in vivo. As with the privilege of no radiation, no harming to patients, MRI should be the most promise medical molecular imaging modality in the future. The MRI molecular probe must be biocompatible, which can participate the normal biologic progress in human body, with no side effects, especially in genetic, It must also overcome the biologic barrier, such as BBB, vascular wall, cell membrane, et al. The conjugation of the molecular target must be high sensitivity and specificity, which can be easily detached, with simple method to use and image. Molecular Image, Magnetic Resonance hnage, Probe, Disease
出处 《中国医疗器械信息》 2008年第5期18-20,32,共4页 China Medical Device Information
基金 国家自然基金(30571781) 上海市科委重点基金(07jc14032 05jc14030)
关键词 分子影像学 MRI 探针 疾病 Molecular Image, Magnetic Resonance Image, Probe, Disease
  • 相关文献

参考文献3

二级参考文献44

  • 1Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media[J]. J Magn Reson Imaging,1977,7(1):68-74.
  • 2Piwnica-Worms D. Molecular imaging[C]. Orlando, Florida: The 48th Annual Meeting of the Association of University Radiologists, 2000.6-9.
  • 3Weissleder R, Mahmood U. Molecular imaging[J]. Radiology,2001,219(2):316-333.
  • 4傅松滨.医学生物学[M].北京:人民卫生出版社,2004.16-56.
  • 5Lee JM, Kim CS, Youk JH. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging[J]. Korean J Radiol,2003,4(1):9-18.
  • 6Vogl TJ, Schwarz W, Blume S. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US[J]. Eur Radiol,2003,13(2):262-272.
  • 7Hahn PF, Saini S. Liver-specific MR imaging contrast agents[J]. Radiol Clin North Am,1998,36(2):287-297.
  • 8Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions[J]. Eur Radiol,1998,8(7):1198-1204.
  • 9Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions[J]. Radiology,1995,196(2):481-488.
  • 10Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography[J]. Radiology,1996,200(3):785-792.

共引文献14

同被引文献40

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部